Cited by 885Genetic Neurodegenerative DiseasesMetabolism and Genetic DisordersMitochondrial Function and Pathology

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, Susan E., Bowling, Allen C., Macgarvey, Usha, Baik, M. Jay, Berger, Stephanie C., Muquit, Miratul M. K., Bird, Edward D., Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410410514

Open this paper in CoChat — free account

Abstract

The etiology of the selective neuronal death that occurs in Huntington's disease (HD) is unknown. Several lines of evidence implicate the involvement of energetic defects and oxidative damage in the disease process, including a recent study that demonstrated an interaction between huntingtin protein and the glycolytic enzyme glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH). Using spectrophotometric assays in postmortem brain tissue, we found evidence of impaired oxidative phosphorylation enzyme activities restricted to the basal ganglia in HD brain, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum). Citrate synthase‐corrected complex II‐III activity was markedly reduced in both HD caudate (−29%) and putamen (−67%), and complex IV activity was reduced in HD putamen (−62%). Complex I and GAPDH activities were unaltered in all regions examined. We also measured levels of the oxidative damage product 8‐hydroxydeoxyguanosine (OH 8 dG) in nuclear DNA, and superoxide dismutase (SOD) activity. OH 8 dG levels were significantly increased in HD caudate. Cytosolic SOD activity was slightly reduced in HD parietal cortex and cerebellum, whereas particulate SOD activity was unaltered in these regions. These results further support a role for metabolic dysfunction and oxidative damage in the pathogenesis of HD.

Integrity signals

Registry

Crossref · 10.1002/ana.410410514

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citation
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Self-citation
Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 961
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
Self-citation
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency
Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730
PURIFICATION OF AMINE OXIDASE FROM BEEF PLASMA
Tabor, C. W., Tabor, H., & Rosenthal, S. M. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65591-7 · Cited by 725

Show all 41 references

Research works printed but not linked: 1

Tabor CW, 1954, Amine oxidases, J Biol Chem, 208, 645

Sorted by citations

Items 301–400 of 883

Transglutaminase 2 in neurodegenerative disorders
Ruan, Q. (2006) · Frontiers in bioscience · doi:10.2741/2111 · Cited by 71
The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration
Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.128 · Cited by 68
Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3‐nitropropionic acid‐induced striatal damage
Fink, J. S., Kalda, A., Ryu, H., Stack, E. C., Schwarzschild, M. A., Chen, J., & Ferrante, R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02145.x · Cited by 68
Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington's disease
Wang, Y., Guo, X., Ye, K., Orth, M., & Gu, Z. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014610118 · Cited by 36
Mitochondrial toxins and neurodegenerative diseases
Ayala, A. (2006) · Frontiers in bioscience · doi:10.2741/2119 · Cited by 68
Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein
Fox, J. H., Connor, T., Stiles, M. A., Kama, J. A., Lü, Z., Dorsey, K., Liebermann, G., Sapp, E., Cherny, R. A., Banks, M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199448 · Cited by 72
Energy defects in Huntington's disease: Why “in vivo” evidence matters
Liot, G., Valette, J., Pépin, J., Flament, J., & Brouillet, E. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.065 · Cited by 65
Elucidating the role of the A2Aadenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs
Chiu, F., Lin, J.-T., Chuang, C.-Y., Chien, T., Chen, C., Chen, K.-H. S., Hsiao, H., Lin, Y., Chern, Y., & Kuo, H. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv318 · Cited by 66
Peroxisome Proliferator‐Activated Receptor‐γ in Amyotrophic Lateral Sclerosis and Huntington′s Disease
Kiaei, M. (2008) · PPAR Research · doi:10.1155/2008/418765 · Cited by 67
Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats
Ribeiro, C., Grando, V., Dutra, C. S., Wannmacher, C. M., & Wajner, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04199.x · Cited by 73
The Striatum Is the Most Vulnerable Region in the Brain to Mitochondrial Energy Compromise: A Hypothesis to Explain Its Specific Vulnerability
Nishino, H., Hida, H., Kumazaki, M., Shimano, Y., Nakajima, K., SHIMIZU, H., OOIWA, T., & Baba, H. (2000) · Journal of Neurotrauma · doi:10.1089/neu.2000.17.251 · Cited by 67
Heterogeneity of nervous system mitochondria: Location, location, location!
Dubinsky, J. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.020 · Cited by 67
Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation
Teunissen, C. E., Steinbusch, H. W. M., Angevaren, M., Appels, M., Bruijn, C. D., Prickaerts, J., & de Vente, J. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00164-6 · Cited by 66
Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases
Bhatti, G. K., Gupta, A., Pahwa, P., Khullar, N., Singh, S., Navik, U., Kumar, S., Mastana, S. S., Reddy, A. P., Reddy, P. H., et al. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.05.002 · Cited by 66
Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease
Kašparová, S., Sumbalová, Z., Bystrický, P., Kucharská, J., Liptaj, T., Mlynárik, V., & Gvozdjáková, A. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.09.002 · Cited by 65
Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington’s Disease
del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., & Jiménez‐Jiménez, F. J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9110-2 · Cited by 63
Glutathione redox cycle dysregulation in Huntington’s disease knock-in striatal cells
Ribeiro, M., Rosenstock, T. R., Cunha‐Oliveira, T., Ferreira, I. L., Oliveira, C. R., & Rego, A. C. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.004 · Cited by 67
Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington’s disease transgenic mice
Deckel, A. W., Tang, V., Nuttal, D., Gary, K. A., & Elder, R. F. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02550-7 · Cited by 65
The Multifaceted Roles of Zinc in Neuronal Mitochondrial Dysfunction
Liu, H. Y., Gale, J. R., Reynolds, I. J., Weiss, J. H., & Aizenman, E. (2021) · Biomedicines · doi:10.3390/biomedicines9050489 · Cited by 68
Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+entry during NMDA receptor activation
Jacquard, C., Trioulier, Y., Cosker, F., Escartin, C., Bizat, N., Hantraye, P., Cancela, J., Bonvento, G., & Brouillet, E. (2006) · The FASEB Journal · doi:10.1096/fj.05-5085fje · Cited by 66
A Role for Oxidized DNA Precursors in Huntington's Disease–Like Striatal Neurodegeneration
Luca, G. D., Russo, M. T., Degan, P., Tiveron, C., Zijno, A., Meccia, E., Ventura, I., Mattei, E., Nakabeppu, Y., Crescenzi, M., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000266 · Cited by 63
Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease
van Roon‐Mom, W., Pepers, B. A., Hoen, P. A. C. ’., Verwijmeren, C., den Dunnen, J. T., Dorsman, J. C., & van Ommen, G. B. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-84 · Cited by 67
Clinical trials of coenzyme Q10 in neurological disorders
Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62
Mitochondrial dysfunction in the hippocampus of rats caused by chronic oxidative stress
Rodrı́guez-Martı́nez, E., Martı́nez, F., Espinosa-García, M. T., Maldonado, P. D., & Rivas-Arancibia, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.018 · Cited by 62
Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington’s disease patients
Almeida, S., Sarmento‐Ribeiro, A. B., Januário, C., Rego, A. C., & Oliveira, C. R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.009 · Cited by 61
Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Szalárdy, L., Klivènyi, P., Zádori, D., Fülöp, F., Toldi, J., & Vécsei, L. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167365 · Cited by 60
Towards an Understanding of Energy Impairment in Huntington’s Disease Brain
Dubinsky, J. M. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170264 · Cited by 63
FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures
Almeida, S., Domingues, A. M. D. J., RODRIGUES, L., Oliveira, C. R., & Rego, A. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.002 · Cited by 61
6-Hydroxydopamine Injections into the Nigrostriatal Pathway Attenuate Striatal Malonate and 3-Nitropropionic Acid Lesions
Maragos, W. F., Jakel, R. J., Pang, Z., & Geddes, J. W. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6918 · Cited by 61
Bioenergetic dysfunction in Huntington's disease human cybrids
Ferreira, I. L., Cunha‐Oliveira, T., Nascimento, M. V., Ribeiro, M., Proença, M. T., Januário, C., Oliveira, C. R., & Rego, A. C. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.05.024 · Cited by 59
MDH2 produced OAA is a metabolic switch rewiring the fuelling of respiratory chain and TCA cycle
Molinié, T., Cougouilles, E., David, C., Cahoreau, E., Portais, J., & Mourier, A. (2022) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2022.148532 · Cited by 60
Mutations that affect mitochondrial functions and their association with neurodegenerative diseases
Dhillon, V. S., & Fenech, M. F. (2013) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2013.09.001 · Cited by 61
Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies
Ramaswamy, S., Shannon, K. M., & Kordower, J. H. (2007) · Cell Transplantation · doi:10.3727/000000007783464687 · Cited by 59
Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer
Sahoo, B., Arduini, I., Drombosky, K. W., Kodali, R. B., Sanders, L. H., Greenamyre, J. T., & Wetzel, R. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155747 · Cited by 59
Differential susceptibility of mitochondrial complex II to inhibition by oxaloacetate in brain and heart
Степанова, А., Shurubor, Y. I., Valsecchi, F., Manfredi, G., & Galkin, A. S. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.06.002 · Cited by 58
AMPK in Neurodegenerative Diseases
Domise, M., & Vingtdeux, V. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_7 · Cited by 61
Oxidative Stress and Neuronal DNA Fragmentation Mediate Age-Dependent Vulnerability to the Mitochondrial Toxin, 3-Nitropropionic Acid, in the Mouse Striatum
Kim, G. W., & Chan, P. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0327 · Cited by 59
Creatine Supplementation Improves Dopaminergic Cell Survival and Protects against MPP+ Toxicity in an Organotypic Tissue Culture System
Andres, R. H., Ducray, A., Pérez-Bouza, A., Schlattner, U., Huber, A. W., Krebs, S. H., Seiler, R. W., Wallimann, T., & Widmer, H. R. (2005) · Cell Transplantation · doi:10.3727/000000005783982756 · Cited by 59
Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58
The 3‐NP Model of Striatal Neurodegeneration
Brouillet, E. (2014) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0948s67 · Cited by 58
Alzheimer's disease-associated polymorphisms in human OGG1 alter catalytic activity and sensitize cells to DNA damage
Jacob, K. D., Hooten, N. N., Tadokoro, T., Lohani, A., Barnes, J., & Evans, M. K. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.010 · Cited by 59
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington’s disease
Lee, S., Chu, K., Park, J., Kang, L., Ko, S., Jung, K., & Kim, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.035 · Cited by 58
Partial resistance to malonate‐induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length
Hansson, O., Castilho, R. F., Korhonen, L., Lindholm, D., Bates, G. P., & Brundin, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00482.x · Cited by 58
Metabolic Disturbances in Diseases with Neurological Involvement
Duarte, J. M. N. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500238 · Cited by 55
Neuroprotective Effects of White Tea Against Oxidative Stress-Induced Toxicity in Striatal Cells
Almajano, M. P., Vila, I., & Ginés, S. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9252-0 · Cited by 57
From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration
Erpapazoglou, Z., Mouton‐Liger, F., & Corti, O. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.021 · Cited by 59
Mitochondrial Dysfunction in Neurodegenerative Disorders and Ageing
Turner, C., & Schapira, A. H. V. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1249-3_19 · Cited by 56
Role of the AMPK pathway in promoting autophagic flux via modulating mitochondrial dynamics in neurodegenerative diseases: Insight into prion diseases
Shah, S. Z. A., Zhao, D., Hussain, T., & Yang, L. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.004 · Cited by 55
Increased Oxidative DNA Damage in Patients With Alcohol Dependence and Its Correlation With Alcohol Withdrawal Severity
Chen, C.-H., Pan, C., Chen, C., & Huang, M. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01349.x · Cited by 57
Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients
Askeland, G., Dosoudilova, Z., Rodinová, M., Klempíř, J., Lišková, I., Kuśnierczyk, A., Bjørås, M., Nesse, G., Klungland, A., Hansíková, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27985-y · Cited by 53
Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling
Brustovetsky, N. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9188-0 · Cited by 54
Polyglutamine gene function and dysfunction in the ageing brain
Hands, S. L., Sinadinos, C., & Wyttenbach, A. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.05.008 · Cited by 55
Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease
Saydoff, J. A., Liu, L. S., Garcia, R. A. G., Hu, Z., Li, D., & von Borstel, R. W. (2003) · Brain Research · doi:10.1016/j.brainres.2003.09.049 · Cited by 54
Transglutaminase Activity Is Present in Highly Purified Nonsynaptosomal Mouse Brain and Liver Mitochondria
Krasnikov, B. F., Kim, S., McConoughey, S. J., Ryu, H., Xu, H., Stavrovskaya, I. G., Iismaa, S. E., Mearns, B. M., Ratan, R. R., Blass, J. P., et al. (2005) · Biochemistry · doi:10.1021/bi0500877 · Cited by 54
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms
Galas, M., Bizat, N., Cuvelier, L., Bantubungi, K., Brouillet, E., Schiffmann, S. N., & Blum, D. L. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.013 · Cited by 54
Brain Glyceraldehyde-3-Phosphate Dehydrogenase Activity in Human Trinucleotide Repeat Disorders
Kish, S. J., Lopes‐Cendes, Í., Guttman, M., Furukawa, Y., Pandolfo, M., Rouleau, G. A., Ross, B. M., NANCE, M. A., Schut, L. J., Ang, L., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.10.1299 · Cited by 54
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington’s disease
Ryu, J. K., Kim, S. U., & McLarnon, J. G. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.006 · Cited by 62
Valproate is Neuroprotective against Malonate Toxicity in Rat Striatum: An Association with Augmentation of High-Affinity Glutamate Uptake
Morland, C., Debernard, K. A. B., Iversen, E. G., & Hassel, B. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000138666.25305.a7 · Cited by 55
Altered selenium status in Huntington's disease: Neuroprotection by selenite in the N171-82Q mouse model
Lu, Z., Marks, E. S., Chen, J., Moline, J., Barrows, L. F., Raisbeck, M. F., Volitakis, I., Cherny, R. A., Chopra, V., Bush, A. I., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.022 · Cited by 53
The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
Escribano, B. M., Colín-González, A. L., Santamarı́a, A., & Túnez, I. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140806160400 · Cited by 53
Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington’s disease
Chandra, A., Sharma, A., Calingasan, N. Y., White, J. M., Shurubor, Y. I., Yang, X. W., Beal, M. F., & Johri, A. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw095 · Cited by 57
Self-citation
Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates
Fukui, H., & Moraes, C. T. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm023 · Cited by 57
Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice
Fossale, E. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.19.2233 · Cited by 54
Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced Huntington’s-Like Symptoms
Jang, M., Lee, M. J., Kim, C. S., & Cho, I. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/237207 · Cited by 52
Oxidative stress is increased in C. elegans models of Huntington’s disease but does not contribute to polyglutamine toxicity phenotypes
Machiela, E., Dues, D. J., Senchuk, M. M., & Raamsdonk, J. M. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.008 · Cited by 53
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease
Saulle, E., Gubellini, P., Picconi, B., Centonze, D., Tropepi, D., Pisani, A., Morari, M., Marti, M., Rossi, L. C., Papa, M., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.09.013 · Cited by 52
Dysregulation of PGC-1α-Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and Opportunities
McMeekin, L. J., Fox, S. N., Boas, S. M., & Cowell, R. M. (2021) · Cells · doi:10.3390/cells10020352 · Cited by 53
The Role of DNA Damage in Neural Plasticity in Physiology and Neurodegeneration
Konopka, A., & Atkin, J. D. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.836885 · Cited by 56
Mitochondrial DNA–Related Mitochondrial Dysfunction in Neurodegenerative Diseases
Swerdlow, R. H. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-0271-mdrmdi · Cited by 50
Neuronal Death in Cultured Murine Cortical Cells Is Induced by Inhibition of GAPDH and Triosephosphate Isomerase
Sheline, C. T., & Choi, D. W. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0177 · Cited by 51
Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: Mitochondrial dysfunction and neurodegeneration
Hariharan, A., Shetty, S., Shirole, T., & Jagtap, A. G. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.10.004 · Cited by 50
Mitochondrial Inhibitor Models of Huntington’s Disease and Parkinson’s Disease Induce Zinc Accumulation and Are Attenuated by Inhibition of Zinc Neurotoxicity in vitro or in vivo
Sheline, C., Zhu, J., Zhang, W. Y., Shi, C., & Cai, A.-L. (2012) · Neurodegenerative Diseases · doi:10.1159/000336558 · Cited by 46
Oxidative metabolism in YAC128 mouse model of Huntington's disease
Hamilton, J., Pellman, J. J., Brustovetsky, T., Harris, R. A., & Brustovetsky, N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv209 · Cited by 50
Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients
Jędrak, P., Mozolewski, P., Węgrzyn, G., & Wieckowski, M. R. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0308-1 · Cited by 49
Role of PGC-1α in Mitochondrial Quality Control in Neurodegenerative Diseases
Zhang, Q., Lei, Y.-H., Zhou, J.-P., Hou, Y.-Y., Wan, Z., Wang, H., & Meng, H. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02858-6 · Cited by 53
Mechanisms of neuronal cell death in Huntington’s disease
Sawa, A., Tomoda, T., & Bae, B.-I. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072864 · Cited by 48
No Evidence for Increased Oxidative Damage to Lipids, Proteins, or DNA in Huntington's Disease
Alam, Z. I., Halliwell, B. B., & Jenner, P. G. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750840.x · Cited by 50
Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?
Sawa, A. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100223 · Cited by 49
Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics
Jin, J., Gu, H., Anders, N. M., Ren, T., Jiang, M., Tao, M., Peng, Q., Rudek, M. A., & Duan, W. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8412-z · Cited by 50
DNA damage and its links to neuronal aging and degeneration
Delint‐Ramírez, I., & Madabhushi, R. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.001 · Cited by 57
Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease
Chakraborty, J., Nthenge-Ngumbau, D. N., Rajamma, U., & Mohanakumar, K. P. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.01.048 · Cited by 49
Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease
Besson, M. T., Dupont, P., Fridell, Y.-W. C., & Liévens, J.-C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq249 · Cited by 49
Meclizine is neuroprotective in models of Huntington's disease
Gohil, V. M., Offner, N., Walker, J. A., Sheth, S. A., Fossale, E., Gusella, J. F., MacDonald, M. E., Néri, C., & Mootha, V. K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq464 · Cited by 48
Rhes, a striatal-enriched protein, promotes mitophagy via Nix
Sharma, M., Ramírez-Jarquín, U. N., Rivera, O., Kazantzis, M., Eshraghi, M., Shahani, N., Sharma, V., Tapia, R., & Subramaniam, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912868116 · Cited by 49
Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.003 · Cited by 48
The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases
Danta, C. C., & Piplani, P. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942218 · Cited by 48
Abnormalities in the Tricarboxylic Acid Cycle in Huntington Disease and in a Huntington Disease Mouse Model
Naseri, N. N., Xu, H., Bonica, J., Vonsattel, J. P., Cortes, E. P., Park, L. C., Arjomand, J., & Gibson, G. E. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000197 · Cited by 48
Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?
Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 52
Potential application of grape derived polyphenols in Huntington’s disease
Wang, J., Pfleger, C. M., Friedman, L. G., Vittorino, R., Zhao, W., Qian, X., Conley, L. M., Ho, L., & Pasinetti, G. M. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0022-y · Cited by 48
Early Deficits in Glycolysis Are Specific to Striatal Neurons from a Rat Model of Huntington Disease
Gouarné, C., Tardif, G., Tracz, J., Gourdou‐Latyszenok, V., Michaud, M., Clemens, L. E., Yu-Taeger, L., Nguyen, H. P., Bordet, T., & Pruss, R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081528 · Cited by 47
Protein oxidation in Huntington disease
Sorolla, M. A., Colman, M. J. R., Vall‐llaura, N., Tamarit, J., Ros, J., & Cabiscol, E. (2012) · BioFactors · doi:10.1002/biof.1013 · Cited by 48
Free radical biology in neurological manifestations: mechanisms to therapeutics interventions
Tripathi, R. S., Gupta, R. V., Sahu, M., Srivastava, D., Das, A., Ambasta, R. K., & Kumar, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16693-2 · Cited by 54
3‐Ureidopropionate contributes to the neuropathology of 3‐ureidopropionase deficiency and severe propionic aciduria: A hypothesis
Kölker, S., Okun, J. G., Hörster, F., Assmann, B. E., Ahlemeyer, B., Kohlmüller, D., Exner‐Camps, S., Mayatepek, E., Krieglstein, J., & Hoffmann, G. F. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10012 · Cited by 47
Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.
Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M. P., Egan, J. M., & Maudsley, S. R. (2008) · PubMed · doi:10.14670/hh-23.237 · Cited by 46
Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington’s disease
McColgan, P., Seunarine, K. K., Gregory, S., Razi, A., Papoutsi, M., Long, J. D., Mills, J. A., Johnson, E. B., Dürr, A., Roos, R. A. C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92641 · Cited by 46
Mitochondrial Aconitase is a Transglutaminase 2 Substrate: Transglutamination is a Probable Mechanism Contributing to High-Molecular-Weight Aggregates of Aconitase and Loss of Aconitase Activity in Huntington Disease Brain
Kim, S., Marekov, L. N., Bubber, P., Browne, S. E., Stavrovskaya, I. G., Lee, J., Steinert, P. M., Blass, J. P., Beal, M. F., Gibson, G. E., et al. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8796-x · Cited by 46
Self-citation
Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers
da Silva, A. B. G., Almeida, S., Laço, M., Duarte, A. I., Domingues, J., Oliveira, C. R., Januário, C., & Rego, A. C. (2013) · Mitochondrion · doi:10.1016/j.mito.2013.05.006 · Cited by 47
The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease
Blum, D. L., Chern, Y., Domenici, M. R., Buée, L., Lin, C., Rea, W. P., Ferré, S., & Popoli, P. (2018) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2018.0006 · Cited by 48
MITOCHONDRIAL COMPLEX I, II/III, AND IV ACTIVITIES IN FAMILIAL AND SPORADIC PARKINSON'S DISEASE
Hanagasi, H. A., AYRIBAS, D., Baysal, K., & Emre, M. (2005) · International Journal of Neuroscience · doi:10.1080/00207450590523017 · Cited by 45
Dysfunctional mitochondrial respiration in the striatum of the Huntington’s disease transgenic R6/2 mouse model
Aidt, F., Nielsen, S. M. B., Kanters, J. K., Pesta, D. H., Nielsen, T. T., Nørremølle, A., Hasholt, L., Christiansen, M., & Hagen, C. M. (2013) · PLoS Currents · doi:10.1371/currents.hd.d8917b4862929772c5a2f2a34ef1c201 · Cited by 45

Authors: Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F.
Affiliations: Harvard University (US)
McLean Hospital (US)
Corresponding author: Beal, M. Flint
ORCID: Browne, Susan E.
Beal, M. Flint
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-05
Volume: 41
Issue: 5
Pages: 646-653
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410410514
OpenAlex: W2102430316
Cited by: 885
References: 41
Citations by year: 2026: 14 · 2025: 12 · 2024: 18 · 2023: 17 · 2022: 25 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 31 · 2017: 13 · 2016: 47 · 2015: 31 · 2014: 41 · 2013: 37 · 2012: 46
FWCI: 10.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2717 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: Huntington's disease, oxidative damage, metabolic dysfunction, basal ganglia, selective neuronal vulnerability, oxidative phosphorylation, complex IV activity, complex I, glyceraldehyde-3-phosphate dehydrogenase, huntingtin, 8-hydroxy-2'-deoxyguanosine, superoxide dismutase, caudate nucleus, putamen, postmortem brain
MeSH terms: Basal Ganglia, Cerebellum, Cerebral Cortex, DNA, Glyceraldehyde-3-Phosphate Dehydrogenases, Humans, Huntington Disease, Mitochondria, Oxidation-Reduction, Reference Values, Spectrophotometry, Stress, Physiological, Superoxide Dismutase, NAD(P)H Dehydrogenase (Quinone), In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks